July 22, 2010
Bone Turnover Model Presented
A poster titled Semi-mechanistic PK/PD model of the effect of odanacatib, a cathepsin K inhibitor, on bone turnover to characterize lumbar spine bone mineral density in two Phase II studies of postmenopausal women was presented in April 2010 at the International Symposium on Measurement and Kinetics of In Vivo Drug Effects, which was held in Noordwijkerhout, The Netherlands. The poster resulted from collaboration of Cognigen with Merck Research Laboratories.
The subject of the poster was base model development of a semi-mechanistic model of bone turnover to describe creatinine adjusted urinary aminoterminal crosslinked telopeptides of Type I collagen (uNTx), a bone resorption biomarker, and lumbar spine bone mineral density data from two Phase II dose-ranging studies during and after treatment with odanacatib. Odanacatib, a potent, orally active inhibitor of cathepsin K, is under clinical development for treatment of postmenopausal osteoporosis.
